Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mix Vaccine and Standard Therapy in Pancreatic Carcinoma
NCT02338752Phase 2Completed
- Sponsor
- Fuda Cancer Hospital
- Start
- Jan 2015
- Primary completion
- Aug 2015
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic carcinoma (2 arms), sponsored by Fuda Cancer Hospital. Primary endpoint: Efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 at 2 years. Started Jan 2015; status: completed.
02
Conditions
pancreatic carcinoma
Beyond the preview
Go deeper on NCT02338752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02338752.